Updated
Reviewed
Appendix B: Acronyms
Acronym | Name |
---|---|
ACTG | AIDS Clinical Trials Group |
AMP | Adolescent Master Protocol |
ANRS | National Agency for AIDS Research (France) |
ARROW | AntiRetroviral Research fOr Watoto |
ATHENA | AIDS Therapy Evaluation in the Netherlands |
ATLAS | Antiretroviral Therapy as Long-Acting Suppression |
BAN | Breastfeeding, Antiretrovirals, and Nutrition |
CHAPAS | Children with HIV in Africa—Pharmacokinetics and Acceptability of Simple second-line antiretroviral regimens |
CHER | Children with HIV Early Antiretroviral Therapy |
DolPHIN-2 | Dolutegravir in Pregnant HIV Mothers and Their Neonates |
ECHO | Evidence for Contraceptive Options and HIV Outcomes |
ENCORE | Evaluation of Novel Concepts in Optimization of antiRetroviral Efficacy |
EPIICAL | Early-treated Perinatally HIV-infected Individuals: Improving Children’s Actual Life with Novel Immunotherapeutic Strategies |
EPPICC | European Pregnancy and Paediatric Infections Cohort Collaboration |
FLAIR | First Long-Acting Injectable Regimen |
HPTN | HIV Prevention Trials Network |
IeDEA | International Epidemiology Databases to Evaluate AIDS |
IMPAACT | International Maternal Pediatric Adolescent AIDS Clinical Trials |
LATTITUDE | Long-Acting Therapy to Improve Treatment Success in Daily LifE |
MOCHA | More Options for Children and Adolescents |
NADIA | Nucleosides And Darunavir/Dolutegravir in Africa |
NEVEREST | Nevirapine Resistance Study |
ODYSSEY | Once-daily DTG based ART in Young people vS Standard thErapY |
PACTG | Pediatric AIDS Clinical Trials Group |
PAINT | Pediatric Study in Adolescents Investigating a New NNRTI TMC278 |
PENPACT | Trial run in collaboration between PENTA and PACTG/IMPAACT |
PENTA | Paediatric European Network for Treatment of AIDS |
PHACS | Pediatric HIV/AIDS Cohort Study |
PIANO | Paediatric study of Intelence As an NNRTI Option |
PREDICT | Early Versus Deferred Antiretroviral Therapy for Children Older Than 1 Year Infected with HIV |
PROMISE | Promoting Maternal and Infant Survival Everywhere Study |
PROMOTE | PEPFAR PROMise Ongoing Treatment Evaluation |
SBIRT | Screening, Brief Intervention, and Referral to Treatment |
SMILE | Strategy for Maintenance of HIV Suppression with Once Daily Integrate Inhibitor+Darunavir/Ritonavir in Children |
START | Strategic Timing of AntiRetroviral Treatment |
SWORD-1 and SWORD-2 | Regimen Switch to Dolutegravir + Rilpivirine from Current Antiretroviral Regimen in Human Immunodeficiency Virus Type 1 Infected and Virologically Suppressed Adults |
Appendix B: Acronyms
Acronym | Name |
---|---|
ACTG | AIDS Clinical Trials Group |
AMP | Adolescent Master Protocol |
ANRS | National Agency for AIDS Research (France) |
ARROW | AntiRetroviral Research fOr Watoto |
ATHENA | AIDS Therapy Evaluation in the Netherlands |
ATLAS | Antiretroviral Therapy as Long-Acting Suppression |
BAN | Breastfeeding, Antiretrovirals, and Nutrition |
CHAPAS | Children with HIV in Africa—Pharmacokinetics and Acceptability of Simple second-line antiretroviral regimens |
CHER | Children with HIV Early Antiretroviral Therapy |
DolPHIN-2 | Dolutegravir in Pregnant HIV Mothers and Their Neonates |
ECHO | Evidence for Contraceptive Options and HIV Outcomes |
ENCORE | Evaluation of Novel Concepts in Optimization of antiRetroviral Efficacy |
EPIICAL | Early-treated Perinatally HIV-infected Individuals: Improving Children’s Actual Life with Novel Immunotherapeutic Strategies |
EPPICC | European Pregnancy and Paediatric Infections Cohort Collaboration |
FLAIR | First Long-Acting Injectable Regimen |
HPTN | HIV Prevention Trials Network |
IeDEA | International Epidemiology Databases to Evaluate AIDS |
IMPAACT | International Maternal Pediatric Adolescent AIDS Clinical Trials |
LATTITUDE | Long-Acting Therapy to Improve Treatment Success in Daily LifE |
MOCHA | More Options for Children and Adolescents |
NADIA | Nucleosides And Darunavir/Dolutegravir in Africa |
NEVEREST | Nevirapine Resistance Study |
ODYSSEY | Once-daily DTG based ART in Young people vS Standard thErapY |
PACTG | Pediatric AIDS Clinical Trials Group |
PAINT | Pediatric Study in Adolescents Investigating a New NNRTI TMC278 |
PENPACT | Trial run in collaboration between PENTA and PACTG/IMPAACT |
PENTA | Paediatric European Network for Treatment of AIDS |
PHACS | Pediatric HIV/AIDS Cohort Study |
PIANO | Paediatric study of Intelence As an NNRTI Option |
PREDICT | Early Versus Deferred Antiretroviral Therapy for Children Older Than 1 Year Infected with HIV |
PROMISE | Promoting Maternal and Infant Survival Everywhere Study |
PROMOTE | PEPFAR PROMise Ongoing Treatment Evaluation |
SBIRT | Screening, Brief Intervention, and Referral to Treatment |
SMILE | Strategy for Maintenance of HIV Suppression with Once Daily Integrate Inhibitor+Darunavir/Ritonavir in Children |
START | Strategic Timing of AntiRetroviral Treatment |
SWORD-1 and SWORD-2 | Regimen Switch to Dolutegravir + Rilpivirine from Current Antiretroviral Regimen in Human Immunodeficiency Virus Type 1 Infected and Virologically Suppressed Adults |
Download Guidelines
- Section Only PDF (91.66 KB)
- Full Guideline PDF (6.34 MB)
- Recommendations Only PDF (227.38 KB)
- Tables Only PDF (1.03 MB)
- Drug Tables Only PDF (2.38 MB)